Gain detailed insights into the trading activity of Congress members for Kura Oncology on our government trades page. Stay updated on how elected officials are investing in KURA.

Kura Oncology - Government Trades

Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

bz_pharma_briefs

Biotech

News

Health Care

Movers

Trading Ideas

General

KURA

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Baidu Photo by testing on Shutterstock

Earnings

Equities

Eurozone

Commodities

Markets

BIDU

CLCO

PYXS

QUBT

SNOW

Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results

oil-prices-5079975

Intraday Update

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings

Wall Street US stocks

CATX

NVDA

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings

maximus shutter

Pre-Market Outlook

ATKR

CNTA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SCHL

XPOF

Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Caterpillar - logo

Downgrades

Analyst Ratings

EXPD

This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Penny Stocks

Small Cap

ADXN

AEON

AGFY

ALRN

Adtalem Global Education Inc. Common Stock

ATGE

ATPC

BCLI

BORR

CALX

CISS

CNSP

CVLT

IFBD

IMCC

MBIN

MBUU

MOTS

NVVE

NYAX

NYXH

ONMD

PALI

PRTA

PTPI

PXLW

REVB

RVSN

SANM

SIDU

SLNA

SWIN

SXTP

TIVC

WFRD

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales 

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

test-tubes-904546_1280

Movers & Shakers

Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.

Why Cancer-Drug Developer Kura Oncology Stock Is Up

AAOI

CGNT

MSCI

NBTX

SMCI

U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday.

General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday

Global

ANVS

EVAX

GETR

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday.

The Dow traded down 0.05% to 37,886.62 while the NASDAQ rose 0.59% to 15,517.32. The S&amp;P 500 also rose, gaining, 0.29% to 4,878.52.

Dow Edges Lower; US Composite PMI Rises In January

Kura Oncology Inc

Kura Sushi Inc

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kuraray Co Ltd

Press Releases

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Management

Kura Oncology Announces Senior Executive Promotions

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Financing

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

LENZ Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Opthea Limited - American Depositary Shares

Opthea

Organogenesis Holdings

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Relay Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tyra Biosciences

Valneva

Verve Therapeutics

Zymeworks

HC Wainwright & Co.

JMP Securities

Wedbush

Scotiabank

Government Trades

Kura Oncology Inc

top performing KURA trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga